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Abstract
Background The cost utility of treatments of age-related
macular degeneration (AMD) is commonly assessed using
health state transition models defined by levels of visual
acuity. However, there is evidence that another measure of
visual function, contrast sensitivity, may be better associ-
ated with utility than visual acuity. This paper investigates
the difference in cost effectiveness resulting from models
based on visual acuity and contrast sensitivity using the
example of bevacizumab (Avastin) for neovascular AMD.
The implications of the choice of outcome on structural
uncertainty in the model are investigated.
Method Health state transition Markov models based on
levels of visual acuity and contrast sensitivity are used to
represent the costs, health utilities and outcomes of the
Avastin for choroidal neovascular age-related macular
degeneration (ABC) trial. Health states are associated with
costs and utilities based on literature values. Treatment
outcomes from the ABC trial are used to predict transitions
between states in both models. Total costs and quality-
adjusted life-years (QALYs) are calculated for a cohort of
patients treated over a defined number of model cycles.
Results Over a 5-year time horizon, a contrast sensitivity
model predicts a statistically significant (p \ 0.05) 25 %
greater QALY gain than the visual acuity model based on
10,000 Monte Carlo simulations. Bevacizumab is more
effective and less costly than the comparator in the contrast
sensitivity model and the visual acuity model.
Conclusion There is considerable structural uncertainty
associated with the choice of outcome for modelling the
cost effectiveness of AMD treatments. Bevacizumab has a
higher incremental QALY gain and more favourable
incremental cost-effectiveness ratio when cost effective-
ness is assessed using contrast sensitivity outcomes com-
pared with using visual acuity outcomes. Previous cost-
effectiveness analyses may have underestimated the cost
effectiveness of anti-vascular endothelial growth factor
(anti-VEGF) therapy.
Key Points for Decision Makers
A model based on contrast sensitivity outcomes
results in a significantly greater quality-adjusted life-
year gain than a model based on visual acuity
outcomes
The finding has implications for cost-effectiveness
decisions for anti-vascular endothelial growth factor
therapies, which have previously been based on
visual acuity models
1 Introduction
Age-related macular degeneration (AMD) causes the pro-
gressive and irreversible loss of central vision. Patients
may find it harder to read, recognise faces or make out fine
detail, which can have a severe impact on their quality of
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life [1]. Late-stage AMD is the third largest cause of
blindness [2]. In the UK, there are currently estimated to be
513,000 cases of AMD and this number is predicted to
increase to 679,000 cases by 2020 [3].
Neovascular (wet) AMD is caused by the development
of new blood vessels in the macular. Treatment of neo-
vascular AMD with anti-vascular endothelial growth factor
(VEGF) therapy is current clinical practice in the UK
National Health Service (NHS). Spending on the anti-
VEGF ranibizumab (Lucentis, Novartis AG, Switzerland)
accounted for £129 million of the NHS prescribing budget
in 2010, making it the third most costly drug [4].
Economic evaluations of treatments for AMD have
concluded that the two anti-VEGF therapies used within
the NHS, approved ranibizumab and off-label bevacizumab
(Avastin, Roche Holdings AG, Switzerland), are cost
effective at commonly applied thresholds when compared
with photodynamic therapy with verteporfin (vPDT) [5, 6].
A recent head-to-head comparison found no significant
difference between the two drugs in terms of effectiveness
[7].
Previous health economic models, including those used
to develop the UK National Institute for Health and Care
Excellence (NICE)’s guidelines on ranibizumab and peg-
aptanib for AMD, have relied on the association between
visual acuity (VA) and health utility to construct Markov
models [8]. Yet there is evidence that anti-VEGF therapy is
also effective in reducing the deterioration in contrast
sensitivity (CS), another measure of visual function.
A cost-effectiveness model based on CS outcomes may
offer advantages over previous modelling techniques. First,
no single visual function outcome captures health-related
quality of life (HRQoL) in AMD and interventions may
have a differential impact on each outcome. CS has an
independent impact on health utility and has been shown to
be more closely associated with HRQoL than VA. Bans-
back et al. [9] found CS remained a statistically significant
predictor of utility even when VA was included in a
regression model. VA measures the eye’s ability to resolve
fine detail at high contrast, while CS measures the ability to
perceive differences between light and dark [10].
Second, utility values for CS have been reported for bin-
ocular vision, so a model based on this outcome takes
account of visual function in both eyes. Models based on VA
outcomes alone have considered only visual function in the
better-seeing eye, while the impact of the worse-seeing eye
on health utility is uncertain [11]. In clinical practice, the eye
with the disease will be treated, whether this is the better- or
worse-seeing eye, therefore, taking account of vision in both
eyes more closely reflects clinical practice.
There has only been one previous economic evaluation
published that used CS. Bansback et al. investigated the
cost effectiveness of vPDT and estimated an incremental
cost effectiveness of approximately GBP 20,996 per qual-
ity-adjusted life-year (QALY) over 10 years compared
with best supportive care [12].
From the previous model, it was not possible to compare
the implications of using CS or VA on the cost effective-
ness of treatments for AMD because there was no directly
comparable VA model. Furthermore, in recent years, vPDT
has been replaced by anti-VEGF therapy as standard clin-
ical practice to treat AMD, so there is no estimate of the
cost effectiveness of current clinical practice using CS.
The aim of this paper is to investigate how developing state
transition models build around CS health states or VA health
states impacts on the cost utility of treatments for AMD.
The choice of using VA or CS in the model is a case of
structural uncertainty, the impact of which can only be
tested by redesign of the model [13]. In this paper, two
Markov models are developed based on the Avastin (bev-
acizumab) for choroidal neovascular age-related macular
degeneration (ABC) trial, which assessed VA and CS
outcomes in AMD patients (Table 1). Bevacizumab was
compared with standard NHS treatment at the time of the
trial, which was a mixture of vPDT, pegaptanib (Macu-
gen, Pfizer, USA), an alternative anti-VEGF and no
treatment (sham injection) depending on the clinical
diagnosis. The trial demonstrated that bevacizumab was an
effective treatment in terms of both outcomes [14, 15].
2 Methods
2.1 Model Structure
State transition Markov models were constructed to simu-
late the progression of the disease in terms of VA and CS.
The VA model had four states of VA in the better-seeing
eye and a death state. The CS had four states of binocular
CS and a death state (Fig. 1). States were chosen that
represented clinically relevant levels of visual function and
had associated health utilities.
Table 1 Baseline summary of patient demographics in the ABC trial
Bevacizumab
(n = 65)
Comparator
(n = 66)
Gender
Male 26 25
Female 39 41
Mean age (years) 79 81
Mean ETDRS visual acuity in study
eye (logMAR)
0.68 0.64
Mean binocular contrast sensitivity
(log units)
1.26 1.22
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In the models, patients were allowed to move forwards
to a better health state, move backwards to a worse health
state, remain in their current health state or die at each
model cycle. Death was an absorbing state, meaning that
patients could not leave the state.
2.2 Transition Probabilities
Transition probabilities were calculated from patient level
data on VA and CS from the ABC trial (n = 131, Table 2).
Better-seeing eye VA transition rates were approximated
from the study eye. The use of the better-seeing eye to
assess cost effectiveness reflects that quality of life is most
strongly impacted by vision in the better-seeing eye. In the
trial, the study eye was the better-seeing eye for 30 % of
participants. CS measurement was measured monocularly
in the trial, therefore binocular CS transition rates were
estimated using a published algorithm, which estimates
binocular CS to be the square root of the sum of the square
of each eye [16]. Age-specific mortality rates were taken
from the Office for National Statistics rates for England
and Wales for 2009 [17]. The rates were adjusted to take
account of the sex of the cohort using the ratio of partici-
pants in the ABC trial.
The trial measured VA every 6 weeks and CS every
12 weeks for 54 weeks. The cycle length was 6 weeks for
the VA model and 12 weeks for the CS model, reflecting
the ABC trial protocol.
2.3 Utility
SF-6D utility values reported by Espallargues et al. [18]
were applied to the health states in the model. 209 patients
with unilateral or bilateral AMD at a hospital in Sheffield,
UK were asked a series of preference-based questionnaires
and the derived utility values were associated with their
visual function. The SF-6D showed greater sensitivity than
the EQ-5D, but less sensitivity than the HUI-3 to changes
in vision. The SF-6D-derived utilities were chosen over the
HUI-3 because the HUI-3 showed little agreement with
other measures and gave extremely low utility scores
compared with other measures. The HUI-3 reported a
utility of just 0.10 for the worst VA state, compared with
0.63, 0.63 and 0.47 for the EQ-5D, SF-6D and time trade-
off (TTO), respectively. TTO utilities were applied as
sensitivity analyses. The utility values associated with
levels of VA and CS were applied to the model health
states (Table 3).
Fig. 1 Markov models. a Visual acuity states (better seeing eye
logMAR). b Contrast sensitivity states (binocular log units)
Table 2 Transition probabilities between Markov states for bev-
acizumab and comparator
From
1.31–2.00 0.61–1.30 0.31–0.60 B0.30
Visual acuity (better seeing eye logMAR)
To Bevacizumab
1.31–2.00 0.62 0.03 0.00 0.01
0.61–1.30 0.33 0.80 0.10 0.00
0.31–0.60 0.00 0.16 0.72 0.24
B0.30 0.05 0.01 0.17 0.76
Comparator
1.31–2.00 0.85 0.06 0.03 0.00
0.61–1.30 0.11 0.84 0.22 0.05
0.31–0.60 0.04 0.10 0.69 0.63
B0.30 0.00 0.00 0.07 0.32
From
\0.30 0.30–0.90 0.91–1.30 [1.30
Contrast sensitivity (binocular log units)
To Bevacizumab
\0.30 1.00 0.06 0.00 0.00
0.30–0.90 0.00 0.44 0.04 0.00
0.91–1.30 0.00 0.50 0.77 0.11
[1.30 0.00 0.00 0.19 0.89
Comparator
\0.30 1.00 0.03 0.00 0.00
0.30–0.90 0.00 0.67 0.10 0.01
0.91–1.30 0.00 0.31 0.69 0.29
[1.30 0.00 0.00 0.20 0.70
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2.4 Cost
Resource use was estimated from the ABC trial protocol
and presented in British Pounds for a cost year of 2009
(Table 4). Treatment rates were calculated from the trial to
reflect that patients were not treated at every time point. If
treated, costs were incurred from the drug, the examination
and the consultation. Otherwise, only costs associated with
the examination and consultation were incurred. A higher
cost was applied to the first consultation to reflect a more
extensive first visit (Table 5).
Unit costs for drugs were obtained from the British
National Formulary and adjusted for the volumes used in
the ABC trial. Consultation and examination costs were
obtained from other published AMD models [12, 19].
2.5 Perspective
The perspective of the model was the UK NHS and personal
social services (PSS) as recommended in the NICE Guide to
the Methods of Technology Appraisal reference case [20].
Each model had a time horizon of 5 years, which represented
an extension of the 54-week trial follow-up and captures the
long-term costs and effects of the treatments. Because there
is no evidence on the long-term outcomes of anti-VEGF
therapy on either VA or CS, it was assumed that transition
rates estimated from the 54-week trial were maintained to
5 years. A discount rate of 3.5 % for costs and QALYs was
applied as recommended by the UK HM Treasury [21].
The model compared bevacizumab (1.25 mg in 0.05 mL
per injection) with a comparator of mixed standard care in
the UK in 2009 (16 patients received PDT, 38 patients
received pegaptanib, 12 patients received sham injection)
based on clinical assessment in the ABC trial.
2.6 Sensitivity Analysis
Appropriate probability functions were fitted to model
parameters to incorporate uncertainty. Probabilistic
Table 3 Utility values assigned to Markov states
SF-6D utility, mean (SD) TTO utility, mean (SD)
Visual acuity (better-seeing eye, logMAR)
1.31–2.00 0.65 (0.11) 0.60 (0.33)
0.61–1.30 0.66 (0.14) 0.64 (0.30)
0.31–0.60 0.67 (0.14) 0.67 (0.31)
B0.30 0.70 (0.18) 0.73 (0.30)
Contrast sensitivity (binocular, log units)
\0.30 0.65 (0.11) 0.58 (0.32)
0.30–0.90 0.64 (0.14) 0.56 (0.32)
0.91–1.30 0.68 (0.14) 0.70 (0.28)
[1.30 0.73 (0.16) 0.83 (0.25)
Utilities calculated by Espallargues et al. [18]
SD standard deviation, TTO time trade-off
Table 4 Unit costs
Item Units per cycle
(6-week/12-week)
Unit
cost (£)
Cost source
Bevacizumab 0.8/1.6 242.66 BNF
Pegaptanib 1.0/2.0 514.00 BNF
First PDT with
verporfin
0.4/0.8 1,181.00 Bansback
et al. [12]
Subsequent PDT
with verporfin
0.4/0.8 1,113.00 Bansback
et al. [12]
Ophthalmic
antibiotic
0.8/1.6 2.17 BNF
Anaesthetic 0.8/1.6 0.45 BNF
Dilating drops 1.0/2.0 0.45 BNF
Initial consultation 1.0/2.0 179.63 Patel et al.
[19]
Subsequent
consultation
1.0/2.0 49.98 Patel et al.
[19]
Eye examination 1.0/2.0 51.00 Patel et al.
[19]
Optical coherence
tomography
1.0/2.0 44.00 Patel et al.
[19]
BNF British National Formulary, PDT photodynamic therapy
Table 5 Cycle costs
First cycle (£) Subsequent cycle (£)
Visual acuity (6-week cycle)
Bevacizumab
Drug 208 208
Examination 95 95
Consultation 180 50
Total 483 353
Comparator
Drug 374 367
Examination 95 95
Consultation 180 50
Total 649 512
Contrast sensitivity (12-week cycle)
Bevacizumab
Drug 416 416
Examination 191 191
Consultation 230 100
Total 836 707
Comparator
Drug 747 733
Examination 191 191
Consultation 230 100
Total 1,168 1,024
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sensitivity analysis was performed using a Monte Carlo
simulation to randomly sample each parameter [22]. Util-
ities were characterised by a beta distribution, with alpha
and beta parameters defined by the means and standard
deviations of the utilities. Costs were characterised by a
gamma distribution with alpha and beta parameters defined
by the means and standard deviations of the costs. Standard
deviations were not available for costs, therefore they were
assumed to be 10 % of the mean in line with recommended
practice for health economic models [22]. Transition
probabilities were characterised by a Dirichlet distribution.
A cost-effectiveness acceptability curve was constructed to
represent the probability of the treatment proving cost
effective at a given value of health effect [23]. One-way
sensitivity analysis was employed to test structural uncer-
tainty within the model.
3 Results
A higher incremental QALY gain is obtained from the CS
model compared with the VA model. The central estimates
of the probabilistic sensitivity analysis are 0.076 in the CS
model and 0.061 in the VA model, which indicates that
bevacizumab is 25 % more effective using CS outcomes
than the VA outcomes (Table 6). This difference was sta-
tistically significant (p \ 0.05) when 10,000 Monte Carlo
simulations of the model were assessed using an unpaired
t test.
The models indicate that bevacizumab is less costly and
more effective than the comparator treatment over 5 years
using either VA or CS outcomes (bevacizumab dominates
the comparator).
The results remain robust when parameters were varied
in sensitivity analysis. Bevacizumab dominates the com-
parator in all model assumptions varied in the one-way
sensitivity analysis (Table 7). The CS model generates a
higher incremental QALY gain than the VA model in all
Table 6 Central cost-effectiveness results: average of Monte Carlo
analysis (5-year time horizon, 3.5% discount rate for costs and
QALYs)
Comparator Bevacizumab Incremental
Visual acuity
Cost (£) 21,258 14,714 -6,545
QALYs 3.028 3.089 0.061
ICER Bevacizumab dominates
Contrast sensitivity
Cost (£) 20,931 14,490 -6,441
QALYs 3.114 3.190 0.076
ICER Bevacizumab dominates
QALYs quality-adjusted life-years, ICER incremental cost-effective-
ness ratio
Table 7 One-way sensitivity analysis
Parameter Base
case
Sensitivity Costs (£) QALYs Change
in
ICER
(%)
Difference
in QALYs
VA vs. CS
(%)
Comparator Bevacizumab Difference Comparator Bevacizumab Difference
Visual acuity
Base case – – 21,005 14,529 -6,477 2.995 3.053 0.058 –
Utilities SF-6D TTO 21,005 14,529 -6,477 2.905 3.055 0.150 -61
Discount
rate
3.5 % 0 % 22,947 15,868 -7,078 3.273 3.338 0.064 -1
5 % 20,243 14,003 -6,240 2.886 2.942 0.056 0
Time
frame
5 years 2 years 8,911 6,184 -2,727 1.260 1.281 0.021 ?17
10 years 39,345 27,183 -12,162 5.625 5.740 0.115 -5
Starting
age
65
years
80 years 29,342 20,281 -9,061 4.191 4.275 0.084 -3
Contrast sensitivity
Base case – – 20,972 14,500 -6,471 3.125 3.199 0.075 – ?29
Utilities SF-6D TTO 20,972 14,500 -6,471 3.273 3.484 0.211 -65 ?41
Discount
rate
3.5 % 0 % 22,950 15,866 -7,084 3.421 3.503 0.082 -1 ?28
5 % 20,197 13,966 -6,231 3.009 3.081 0.072 0 ?28
Time
frame
5 years 2 years 8,900 6,171 -2,729 1.316 1.344 0.027 ?15 ?30
10 years 39,288 27,139 -12,149 5.869 6.009 0.140 0 ?22
Starting
age
65
years
80 years 29,312 20,255 -9,057 4.374 4.478 0.104 ?1 ?23
VA visual acuity, CS contrast sensitivity, TTO time trade-off, QALYs quality-adjusted life-years, ICER incremental cost-effectiveness ratio
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Fig. 2 Cost-effectiveness plane
of incremental costs and
quality-adjusted life-years
(QALYs) for bevacizumab vs.
comparator. a Visual acuity.
b Contrast sensitivity
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scenarios. The model is most sensitive to the choice of
utility set.
Bevacizumab remains cost effective when a probabi-
listic sensitivity analysis is applied to utilities, costs and
transition probabilities. Figure 2 shows the probabilistic
sensitivity analysis on a cost-effectiveness plane.
The cost-effectiveness acceptability curve (CEAC)
highlights that for the same cost as the comparator, bev-
acizumab has a probability of being cost effective of more
than 60 % when assessed using VA and 65 % when
assessed using CS (Fig. 3). At most values of QALY gain
there is a higher probability of bevacizumab being cost
effective in the CS model than in the VA model.
4 Discussion/Conclusion
The choice of outcome represents a major source of
structural uncertainty when constructing models to assess
the cost effectiveness of treatments for AMD and has been
shown to have a large impact on cost-effectiveness
estimates.
Bevacizumab appears more cost effective when assessed
using CS outcomes rather than VA outcomes. In this trial,
as bevacizumab dominates the comparator, the decision on
the use of bevacizumab in AMD would not be altered by
the choice of outcome used in the model.
The difference in incremental QALY gain between the
CS and VA models when assessing the cost effectiveness
of anti-VEGF therapy is potentially significant in health-
care decision making, particularly in decisions close to the
cost-effectiveness threshold.
Another anti-VEGF therapy, ranibizumab, is currently
recommended for the treatment of AMD patients within the
NHS [8]. It has been shown to be equally effective to
bevacizumab, but is more costly [7, 24]. In NICE’s eco-
nomic evaluation of ranibizumab for AMD, the assessment
group used a state transition model based on VA. The base-
case incremental cost-effectiveness ratios (ICERs) over a
10-year time horizon for predominantly classic lesions
were £15,638 per QALY gained compared with PDT, and
£11,412 per QALY gained compared with best supportive
care. For minimally classic lesions and occult no classic
lesions, assuming 2 years of treatment, the ICER was
£25,098 per QALY gained compared with best supportive
care [5].
Although a direct comparison between the appraisal
results and this study is not possible because of a different
intervention and comparator, an improvement in cost
effectiveness of 25 % could have implications on decision
making at a threshold of £20,000–£30,000 per QALY,
particularly in subgroups with minimally classic lesions
and occult no classic lesions.
Traditionally, a CEAC such as that shown in Fig. 3
would only show positive values of health effects.
Fig. 3 Cost-effectiveness
acceptability curve for
bevacizumab vs. comparator.
CS contrast sensitivity,
VA visual acuity
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However, the negative value of health effect is shown to
allow inferences to be made about how the two outcomes
may impact on the cost effectiveness of a more costly drug.
The CEAC demonstrates that for a given value of health
effect, the CS model predicts bevacizumab to be more
likely to be considered cost effective.
There are two potential reasons for the different QALY
estimates from the two models. First, the closer association
between CS and HRQoL may mean that the CS model is
more accurately representing the utility gain of the treat-
ment than the VA model. Alternatively, the intervention
may have a differential effect on VA and CS and anti-
VEGF therapy may improve CS more than VA in terms of
relative utility.
There are a number of limitations with this study. The
comparator treatment (a mixture of pegaptanib, PDT and
no treatment) as used in the ABC trial is no longer standard
NHS practice because of the approval of ranibizumab. This
limits interpretation of the absolute ICERs. A comparison
of bevacizumab with ranibizumab based on CS outcomes
would be a valuable area for future research. Furthermore,
another anti-VEGF therapy, aflibercept (Eylea Bayer), is
approved for the treatment of AMD in the US and has been
shown to be equally effective compared with ranibizumab
[25].
Both VA and CS have limitations when measuring very
poor vision. Both measures rely on patients reading letters
on a chart, so when patients cannot read the first letter,
patients are assumed to have the most severe health state in
the model.
Transition rates were based on trial data and allowed
patients’ vision to worsen, remain the same or improve at
each cycle. Anti-VEGF therapy is generally believed to
maintain or reduce deterioration in vision rather than
improve it. However, the nature of VA and CS as perfor-
mance measures means there may be variation in the exact
scores achieved by patients on each visit.
These models do not include adverse events. Of the 131
patients enrolled in the ABC trial, five patients did not
complete the study because of adverse events, loss to fol-
low-up or death. The ocular safety profiles for the two
treatment groups showed no overall imbalance in serious
and non-serious ocular adverse events. Given the incidence
of any adverse events in the two models would be the
same, their exclusion from the models should not impact
on the difference between VA and CS identified.
Generally, these results highlight that the choice of
clinical outcome on which a model is based can have a
large impact on the cost-effectiveness estimates of the
model. The uncertainty associated with the choice of
clinical variable to associate with utility cannot be assigned
a distribution and tested using a probabilistic sensitivity
analysis, as is frequently done for costs, utilities and
transition rates. Attention should be paid to the association
between clinical disease states and HRQoL when devel-
oping health economic models. The clinical outcome that is
best associated with HRQoL in the condition should be
used where practical. If there is uncertainty over the most
suitable clinical outcome for defining model states, the
alternatives could be presented in a one-way sensitivity
analysis.
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